JP7224307B2 - 胆汁酸誘導体の調製のための方法及び中間体 - Google Patents

胆汁酸誘導体の調製のための方法及び中間体 Download PDF

Info

Publication number
JP7224307B2
JP7224307B2 JP2019570461A JP2019570461A JP7224307B2 JP 7224307 B2 JP7224307 B2 JP 7224307B2 JP 2019570461 A JP2019570461 A JP 2019570461A JP 2019570461 A JP2019570461 A JP 2019570461A JP 7224307 B2 JP7224307 B2 JP 7224307B2
Authority
JP
Japan
Prior art keywords
compound
formula
compounds
reacting
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019570461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525426A5 (enExample
JP2020525426A (ja
Inventor
ロベルト ペッリッチャリ，
アンティーモ ジョイエッロ，
ガブリエル ガルビン，
ロナルド ディー． ルイス，
マシュー ヤニック，
ミョン グ キム，
フレッド ロナルド ルーシンク，
バルチャン コニング，
トーマス ヘンゼル，
Original Assignee
インターセプト ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターセプト ファーマシューティカルズ， インコーポレイテッド filed Critical インターセプト ファーマシューティカルズ， インコーポレイテッド
Publication of JP2020525426A publication Critical patent/JP2020525426A/ja
Publication of JP2020525426A5 publication Critical patent/JP2020525426A5/ja
Application granted granted Critical
Publication of JP7224307B2 publication Critical patent/JP7224307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2019570461A 2017-06-23 2018-06-22 胆汁酸誘導体の調製のための方法及び中間体 Active JP7224307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523937P 2017-06-23 2017-06-23
US62/523,937 2017-06-23
PCT/US2018/039148 WO2018237350A1 (en) 2017-06-23 2018-06-22 METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2020525426A JP2020525426A (ja) 2020-08-27
JP2020525426A5 JP2020525426A5 (enExample) 2021-07-26
JP7224307B2 true JP7224307B2 (ja) 2023-02-17

Family

ID=64691408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570461A Active JP7224307B2 (ja) 2017-06-23 2018-06-22 胆汁酸誘導体の調製のための方法及び中間体

Country Status (10)

Country Link
US (2) US11066437B2 (enExample)
EP (1) EP3642217A4 (enExample)
JP (1) JP7224307B2 (enExample)
KR (2) KR102831293B1 (enExample)
CN (1) CN110945006A (enExample)
AU (1) AU2018288883B2 (enExample)
BR (1) BR112019027458A2 (enExample)
CA (1) CA3067219A1 (enExample)
IL (2) IL271343B2 (enExample)
WO (1) WO2018237350A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036835A1 (en) 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SMT202100476T1 (it) 2015-07-06 2021-09-14 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
BR112018000129B1 (pt) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
TN2018000106A1 (en) * 2015-10-07 2019-10-04 Intercept Pharmaceuticals Inc Farnesoid x receptor modulators
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
MX392270B (es) 2016-09-30 2025-03-24 Sage Therapeutics Inc Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CN110267966B (zh) 2016-10-18 2022-07-08 萨奇治疗股份有限公司 氧甾醇及其使用方法
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
WO2021155167A1 (en) * 2020-01-31 2021-08-05 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
US12215127B2 (en) 2020-04-17 2025-02-04 Cornell University Compositions and methods for profiling of gut microbiota-associated bile salt hydrolase (BSH) activity
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN112795615A (zh) * 2021-02-03 2021-05-14 湖南醇康医药科技有限公司 一种诱变菌种以及微生物发酵制备熊去氧胆酸的方法
WO2023288123A1 (en) * 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN114045239B (zh) * 2021-11-08 2023-09-29 浙江树人学院（浙江树人大学） 具有二甲基乙酰胺降解能力的泛养副球菌ybh-7及应用
AU2023257308A1 (en) * 2022-04-21 2024-10-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2024163640A2 (en) * 2023-02-01 2024-08-08 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107973834A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 作为fxr/tgr5调节剂的胆酸衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US2554882A (en) 1943-02-04 1951-05-29 Reichstein Tadeus 3-hydroxy-11-ketoetiocholanic acid and its esters
US3277121A (en) 1964-05-04 1966-10-04 Canada Packers Ltd Conversion of delta11-steroids to 11-oxygenated steroids
DE3040634A1 (de) 1980-10-29 1982-05-27 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 3 (alpha) -hydroxy-5- (beta) -pregnan-11,20-dion
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
HRP20180931T1 (hr) 2013-05-14 2018-10-05 Intercept Pharmaceuticals, Inc. 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x
CA2966885A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
HK1244708A1 (zh) 2014-11-26 2018-08-17 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
RU2017130466A (ru) 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
NZ735126A (en) 2015-03-31 2022-10-28 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112018002499A2 (pt) 2015-08-07 2018-09-18 Intercept Pharmaceuticals Inc método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
TN2018000106A1 (en) 2015-10-07 2019-10-04 Intercept Pharmaceuticals Inc Farnesoid x receptor modulators
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107973834A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 作为fxr/tgr5调节剂的胆酸衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PELLICCIARI, R et al.，Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure - Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid，Journal of Medicinal Chemistry，2004年，Vol. 47，pp. 4559-4569
PELLICCIARI, R. et al.，Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure - Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid，Journal of Medicinal Chemistry，2004年，Vol. 47, No.18，pp.4559-4569

Also Published As

Publication number Publication date
IL271343B1 (en) 2023-08-01
BR112019027458A2 (pt) 2020-07-07
CA3067219A1 (en) 2018-12-27
KR20250109791A (ko) 2025-07-17
WO2018237350A1 (en) 2018-12-27
AU2018288883A1 (en) 2020-01-16
US11066437B2 (en) 2021-07-20
IL271343B2 (en) 2023-12-01
AU2018288883B2 (en) 2022-06-02
EP3642217A1 (en) 2020-04-29
US20220127302A1 (en) 2022-04-28
IL271343A (en) 2020-01-30
KR20200020877A (ko) 2020-02-26
KR102831293B1 (ko) 2025-07-08
US20180371009A1 (en) 2018-12-27
JP2020525426A (ja) 2020-08-27
IL304455A (en) 2023-09-01
EP3642217A4 (en) 2021-06-16
CN110945006A (zh) 2020-03-31

Similar Documents

Publication Publication Date Title
JP7224307B2 (ja) 胆汁酸誘導体の調製のための方法及び中間体
AU2016335765B2 (en) Farnesoid X receptor modulators
KR102527821B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
CN103965277B (zh) 一种从甾醇发酵物合成二氟泼尼酯的方法
AU2016297821B2 (en) Methods for preparation of bile acids and derivatives thereof
CN102482315A (zh) 肝x受体激动剂
JP2018528230A (ja) 胆汁酸誘導体の調製のための方法および中間体
Sepe et al. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity
CN103787942B (zh) 一种制备鲁比前列酮的中间体、其制备方法以及通过其制备鲁比前列酮的方法
HK1080088A1 (zh) 制备c-7取代的5-雄甾烯的方法
US20130102580A1 (en) Compositions and methods related to deoxycholic acid and its polymorphs
WO2024163640A2 (en) Methods and intermediates for the preparation of bile acid derivatives
CN101508717B (zh) 抗结核化合物帕格甾醇的合成方法
Durán et al. Synthesis of 6-thia analogs of the natural neurosteroid allopregnanolone
CN101676296B (zh) 制备21位羧酸酯甾体化合物的方法及使用该方法制备的甾体化合物
WO2023288123A1 (en) Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
Das et al. Improvements in corticosteroid 21-acetoxy-17α-hydroxy-16α-methyl-pregna-1, 4, 9 (11)-triene-3, 20-dione synthesis and its use as common intermediate in the synthesis of some impurities related to dexamethasone and mometasone
Martínez et al. Synthesis of 6-azaprogesterone and 19-hydroxy-6-azasteroids
Bunyathaworn et al. Synthesis and Cytotoxicity Studies of Polyhydroxysterols and Their Sulfate Analogs
JPH10251294A (ja) シス−ステロール化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210603

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230207

R150 Certificate of patent or registration of utility model

Ref document number: 7224307

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150